PDF herunterladen
Semin Neurol 2017; 37(02): 215-227
DOI: 10.1055/s-0037-1602422
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recognizing Atypical Parkinsonisms: “Red Flags” and Therapeutic Approaches

Nikolaus R. McFarland
1   Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida College of Medicine, Gainesville, Florida
,
Christopher W. Hess
1   Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida College of Medicine, Gainesville, Florida
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Mai 2017 (online)

    Lizenzen und Reprints

Abstract

The overlap of signs and symptoms between Parkinson's disease and the atypical parkinsonian syndromes, such as progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome and dementia with Lewy bodies, can render clinical diagnoses challenging. The continued evolution of diagnostic criteria to reflect the increasingly recognized heterogeneous presentations of these diseases further complicates timely recognition and diagnosis. In this review, we provide a diagnostic approach to the classic atypical parkinsonian syndromes, with an emphasis on the key clinical and pathological features of each and the recognition of “red flags” in the setting of recent advances in diagnosis and treatment.

Keywords

Parkinson's disease - atypical parkinsonism - proteinopathy - neurodegeneration - multidisciplinary care
 

  • References

  • 1 Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993; 39: 165-172
    PubMedGoogle Scholar
  • 2 Litvan I, MacIntyre A, Goetz CG. , et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55 (07) 969-978
    CrossrefPubMedGoogle Scholar
  • 3 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55 (03) 181-184
    CrossrefPubMedGoogle Scholar
  • 4 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57 (08) 1497-1499
    CrossrefPubMedGoogle Scholar
  • 5 Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci 1991; 18 (03) 275-278
    CrossrefPubMedGoogle Scholar
  • 6 Adler CH, Beach TG, Hentz JG. , et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014; 83 (05) 406-412
    CrossrefPubMedGoogle Scholar
  • 7 Mark MH, Dickson DW, Sage JI, Duvoisin RC. The clinicopathologic spectrum of Lewy body disease. Adv Neurol 1996; 69: 315-318
    PubMedGoogle Scholar
  • 8 Postuma RB, Berg D, Stern M. , et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30 (12) 1591-1601
    CrossrefPubMedGoogle Scholar
  • 9 Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogenous system degeneration”. Trans Am Neurol Assoc 1963; 88: 25-29
    PubMedGoogle Scholar
  • 10 Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354 (9192): 1771-1775
    CrossrefPubMedGoogle Scholar
  • 11 Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38 (07) 1031-1034
    CrossrefPubMedGoogle Scholar
  • 12 Nath U, Ben-Shlomo Y, Thomson RG. , et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124 (Pt 7): 1438-1449
    CrossrefPubMedGoogle Scholar
  • 13 Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49 (05) 1284-1288
    CrossrefPubMedGoogle Scholar
  • 14 Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003; 18 (09) 1018-1026
    CrossrefPubMedGoogle Scholar
  • 15 Pastor P, Tolosa E. Progressive supranuclear palsy: clinical and genetic aspects. Curr Opin Neurol 2002; 15 (04) 429-437
    CrossrefPubMedGoogle Scholar
  • 16 Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006; 77 (04) 468-473
    CrossrefPubMedGoogle Scholar
  • 17 Brett FM, Henson C, Staunton H. Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology. Arch Neurol 2002; 59 (03) 464-467
    CrossrefPubMedGoogle Scholar
  • 18 Batla A, Nehru R, Vijay T. Vertical wrinkling of the forehead or Procerus sign in Progressive Supranuclear Palsy. J Neurol Sci 2010; 298 (1-2): 148-149
    CrossrefPubMedGoogle Scholar
  • 19 Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47 (05) 1184-1189
    CrossrefPubMedGoogle Scholar
  • 20 Strowd RE, Cartwright MS, Okun MS, Haq I, Siddiqui MS. Pseudobulbar affect: prevalence and quality of life impact in movement disorders. J Neurol 2010; 257 (08) 1382-1387
    CrossrefPubMedGoogle Scholar
  • 21 Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001; 56 (07) 957-963
    CrossrefPubMedGoogle Scholar
  • 22 Litvan I, Hauw JJ, Bartko JJ. , et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996; 55 (01) 97-105
    CrossrefPubMedGoogle Scholar
  • 23 Kanazawa M, Shimohata T, Toyoshima Y. , et al. Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study. Mov Disord 2009; 24 (09) 1312-1318
    CrossrefPubMedGoogle Scholar
  • 24 Respondek G, Stamelou M, Kurz C. , et al; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14) 1758-1766
    CrossrefPubMedGoogle Scholar
  • 25 Williams DR, de Silva R, Paviour DC. , et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128 (Pt 6): 1247-1258
    CrossrefPubMedGoogle Scholar
  • 26 Mizusawa H, Mochizuki A, Ohkoshi N. , et al. Progressive supranuclear palsy presenting with pure akinesia. Adv Neurol 1993; 60: 618-621
    PubMedGoogle Scholar
  • 27 Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22 (15) 2235-2241
    CrossrefPubMedGoogle Scholar
  • 28 Armstrong MJ, Litvan I, Lang AE. , et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (05) 496-503
    CrossrefPubMedGoogle Scholar
  • 29 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8 (03) 270-279
    CrossrefPubMedGoogle Scholar
  • 30 Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase 2012; 18 (06) 478-488
    CrossrefPubMedGoogle Scholar
  • 31 Donker Kaat L, Boon AJ, Azmani A. , et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology 2009; 73 (02) 98-105
    CrossrefPubMedGoogle Scholar
  • 32 King A, Curran O, Al-Sarraj S. Atypical progressive supranuclear palsy presenting as primary lateral sclerosis. J Neurol Sci 2013; 329 (1-2): 69
    CrossrefPubMedGoogle Scholar
  • 33 Nagao S, Yokota O, Nanba R. , et al. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. J Neurol Sci 2012; 323 (1-2): 147-153
    CrossrefPubMedGoogle Scholar
  • 34 Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23 (04) 394-400
    CrossrefPubMedGoogle Scholar
  • 35 Jellinger K. Cerebellar involvement in progressive supranuclear palsy. Mov Disord 2010; 25 (08) 1104-1105
    CrossrefPubMedGoogle Scholar
  • 36 Stamelou M, de Silva R, Arias-Carrión O. , et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133 (Pt 6): 1578-1590
    CrossrefPubMedGoogle Scholar
  • 37 Höglinger GU, Melhem NM, Dickson DW. , et al; PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43 (07) 699-705
    CrossrefPubMedGoogle Scholar
  • 38 Oba H, Yagishita A, Terada H. , et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64 (12) 2050-2055
    CrossrefPubMedGoogle Scholar
  • 39 Gröschel K, Kastrup A, Litvan I, Schulz JB. Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 2006; 66 (06) 949-950
    CrossrefPubMedGoogle Scholar
  • 40 Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006; 129 (Pt 4): 1040-1049
    CrossrefPubMedGoogle Scholar
  • 41 Paviour DC, Thornton JS, Lees AJ, Jäger HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007; 22 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 42 Slowinski J, Imamura A, Uitti RJ. , et al. MR imaging of brainstem atrophy in progressive supranuclear palsy. J Neurol 2008; 255 (01) 37-44
    PubMedGoogle Scholar
  • 43 Tsuboi Y, Slowinski J, Josephs KA, Honer WG, Wszolek ZK, Dickson DW. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2003; 60 (11) 1766-1769
    CrossrefPubMedGoogle Scholar
  • 44 Longoni G, Agosta F, Kostić VS. , et al. MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord 2011; 26 (02) 247-255
    CrossrefPubMedGoogle Scholar
  • 45 Knake S, Belke M, Menzler K. , et al. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Mov Disord 2010; 25 (09) 1232-1238
    CrossrefPubMedGoogle Scholar
  • 46 Renard D, Collombier L, Castelnovo G, Labauge P. Teaching NeuroImages: FDG-PET in progressive supranuclear palsy. Neurology 2010; 74 (14) e60
    CrossrefPubMedGoogle Scholar
  • 47 Ariza M, Kolb HC, Moechars D, Rombouts F, Andrés JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem 2015; 58 (11) 4365-4382
    CrossrefPubMedGoogle Scholar
  • 48 Rajrut AH, Uitti RJ, Fenton ME. , et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997; 3: 211-214
    CrossrefPubMedGoogle Scholar
  • 49 Stamelou M, Reuss A, Pilatus U. , et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23 (07) 942-949
    CrossrefPubMedGoogle Scholar
  • 50 Apetauerova D, Scala SA, Hamill RW. , et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016; 3 (05) e266
    CrossrefPubMedGoogle Scholar
  • 51 Wenning GK, Litvan I, Jankovic J. , et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64 (02) 184-189
    CrossrefPubMedGoogle Scholar
  • 52 Litvan I, Agid Y, Goetz C. , et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 1997; 48 (01) 119-125
    CrossrefPubMedGoogle Scholar
  • 53 Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18 (11) 1224-1232
    CrossrefPubMedGoogle Scholar
  • 54 Pillon B, Gouider-Khouja N, Deweer B. , et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995; 58 (02) 174-179
    CrossrefPubMedGoogle Scholar
  • 55 Dickson DW, Bergeron C, Chin SS. , et al; Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61 (11) 935-946
    CrossrefPubMedGoogle Scholar
  • 56 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7 (05) 263-272
    CrossrefPubMedGoogle Scholar
  • 57 Whitwell JL, Jack Jr CR, Boeve BF. , et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75 (21) 1879-1887
    CrossrefPubMedGoogle Scholar
  • 58 Murray ME, Kouri N, Lin WL, Jack Jr CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6 (01) 1
    CrossrefPubMedGoogle Scholar
  • 59 Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8 (12) 1172-1178
    CrossrefPubMedGoogle Scholar
  • 60 Gilman S, Wenning GK, Low PA. , et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71 (09) 670-676
    CrossrefPubMedGoogle Scholar
  • 61 Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015; 372 (03) 249-263
    CrossrefPubMedGoogle Scholar
  • 62 Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3 (02) 93-103
    CrossrefPubMedGoogle Scholar
  • 63 Wenning GK, Geser F, Krismer F. , et al; European Multiple System Atrophy Study Group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12 (03) 264-274
    CrossrefPubMedGoogle Scholar
  • 64 Köllensperger M, Geser F, Seppi K. , et al; European MSA Study Group. Red flags for multiple system atrophy. Mov Disord 2008; 23 (08) 1093-1099
    CrossrefPubMedGoogle Scholar
  • 65 Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 2012; 11 (04) 361-368
    CrossrefPubMedGoogle Scholar
  • 66 Köllensperger M, Geser F, Ndayisaba JP. , et al; EMSA-SG. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25 (15) 2604-2612
    CrossrefPubMedGoogle Scholar
  • 67 Brown RG, Lacomblez L, Landwehrmeyer BG. , et al; NNIPPS Study Group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133 (Pt 8): 2382-2393
    CrossrefPubMedGoogle Scholar
  • 68 Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 2005; 109 (02) 129-140
    CrossrefPubMedGoogle Scholar
  • 69 Ahmed Z, Asi YT, Sailer A. , et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012; 38 (01) 4-24
    CrossrefPubMedGoogle Scholar
  • 70 Brooks DJ, Seppi K. ; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24 (07) 949-964
    CrossrefPubMedGoogle Scholar
  • 71 Tha KK, Terae S, Tsukahara A. , et al. Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol 2012; 12: 39
    CrossrefPubMedGoogle Scholar
  • 72 Bhattacharya K, Saadia D, Eisenkraft B. , et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002; 59 (05) 835-842
    PubMedGoogle Scholar
  • 73 Perju-Dumbrava LD, Kovacs GG, Pirker S. , et al. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord 2012; 27 (01) 65-71
    CrossrefPubMedGoogle Scholar
  • 74 Planetta PJ, Kurani AS, Shukla P. , et al. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp 2015; 36 (03) 1165-1179
    CrossrefPubMedGoogle Scholar
  • 75 Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24 (11) 1650-1655
    CrossrefPubMedGoogle Scholar
  • 76 Gilman S, Low PA, Quinn N. , et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163 (01) 94-98
    CrossrefPubMedGoogle Scholar
  • 77 Poewe W, Seppi K, Fitzer-Attas CJ. , et al; Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015; 14 (02) 145-152
    CrossrefPubMedGoogle Scholar
  • 78 Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997; 3 (04) 211-214
    CrossrefPubMedGoogle Scholar
  • 79 McKeith IG, Dickson DW, Lowe J. , et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-1872
    CrossrefPubMedGoogle Scholar
  • 80 DelleDonne A, Klos KJ, Fujishiro H. , et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65 (08) 1074-1080
    PubMedGoogle Scholar
  • 81 Gibb WR. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol 1986; 12 (03) 223-234
    CrossrefPubMedGoogle Scholar
  • 82 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51 (06) 745-752
    CrossrefPubMedGoogle Scholar
  • 83 Hurtig HI, Trojanowski JQ, Galvin J. , et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54 (10) 1916-1921
    CrossrefPubMedGoogle Scholar
  • 84 Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64 (08) 1404-1410
    CrossrefPubMedGoogle Scholar
  • 85 Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007; 13 (Suppl. 03) S221-S224
    CrossrefPubMedGoogle Scholar
  • 86 Sinha N, Firbank M, O'Brien JT. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 2012; 27 (05) 443-453
    CrossrefPubMedGoogle Scholar
  • 87 Whitwell JL, Weigand SD, Shiung MM. , et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007; 130 (Pt 3): 708-719
    CrossrefPubMedGoogle Scholar
  • 88 Graff-Radford J, Murray ME, Lowe VJ. , et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology 2014; 83 (09) 801-809
    CrossrefPubMedGoogle Scholar
  • 89 Gomperts SN, Rentz DM, Moran E. , et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71 (12) 903-910
    CrossrefPubMedGoogle Scholar
  • 90 Mollenhauer B, Bibl M, Trenkwalder C. , et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm (Vienna) 2005; 112 (07) 933-948
    CrossrefPubMedGoogle Scholar
  • 91 Hack N, Fayad SM, Monari EH. , et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One 2014; 9 (03) e91545
    CrossrefPubMedGoogle Scholar
  • 92 Cummings J, Isaacson S, Mills R. , et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383 (9916): 533-540
    CrossrefPubMedGoogle Scholar
  • 93 Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3 (03) CD006504
    PubMedGoogle Scholar
  • 94 Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341 (07) 543-544
    CrossrefPubMedGoogle Scholar
  • 95 Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci 2010; 17 (03) 385-386
    CrossrefPubMedGoogle Scholar